Duchenne News

February 16, 2024
Sarepta announces the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application for ELEVIDYS.
February 13, 2024
Edgewise shares a press release announcing FDA granting Fast Track designation for EDG-5506 for the treatment of Duchenne.
February 8, 2024
REGENXBIO announces completion of enrollment in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202.
January 8, 2024
PepGen announces first patient dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose clinical trial.
December 19, 2023
Wave Life Sciences Community Letter with information on Phase 2 FORWARD-53 study for Duchenne.
December 19, 2023
Edgewise announces launch of educational website dedicated to the Becker muscular dystrophy community.
December 19, 2023
Edgewise releases Winter 2023 newsletter.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open